Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) has earned a consensus recommendation of “Hold” from the eight analysts that are covering the company. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $1.15.

A number of research firms have issued reports on TKAI. Janney Montgomery Scott cut shares of Tokai Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 26th. William Blair cut shares of Tokai Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, July 26th. Stifel Nicolaus cut shares of Tokai Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Wells Fargo & Co. cut shares of Tokai Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, July 26th. Finally, BMO Capital Markets cut shares of Tokai Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, July 26th.

Tokai Pharmaceuticals (NASDAQ:TKAI) traded up 1.94% during midday trading on Monday, hitting $1.58. 637,752 shares of the company were exchanged. The stock has a 50 day moving average of $1.29 and a 200 day moving average of $4.47. The firm’s market capitalization is $35.76 million. Tokai Pharmaceuticals has a 1-year low of $0.98 and a 1-year high of $12.93.

Several large investors have recently made changes to their positions in TKAI. ProShare Advisors LLC raised its stake in shares of Tokai Pharmaceuticals by 1.7% in the second quarter. ProShare Advisors LLC now owns 18,060 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 301 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Tokai Pharmaceuticals by 3.0% in the second quarter. California State Teachers Retirement System now owns 20,803 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 600 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Tokai Pharmaceuticals by 6.0% in the second quarter. Bank of New York Mellon Corp now owns 38,310 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 2,168 shares during the last quarter. State Street Corp raised its stake in shares of Tokai Pharmaceuticals by 7.2% in the first quarter. State Street Corp now owns 86,767 shares of the biopharmaceutical company’s stock worth $487,000 after buying an additional 5,854 shares during the last quarter. Finally, Bridgeway Capital Management Inc. raised its stake in shares of Tokai Pharmaceuticals by 66.7% in the second quarter. Bridgeway Capital Management Inc. now owns 100,000 shares of the biopharmaceutical company’s stock worth $551,000 after buying an additional 40,000 shares during the last quarter. 23.81% of the stock is currently owned by hedge funds and other institutional investors.

About Tokai Pharmaceuticals

Tokai Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation.

5 Day Chart for NASDAQ:TKAI

Receive News & Stock Ratings for Tokai Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tokai Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.